Table 2.

Exposure to rufinamide and risk of CNS adverse events: meta-analysis of somnolence

Study characteristics			Rufinamide		Placebo		Risk ratio	Weight
Study number	Authors	Year	Events	Total	Events	Total	M-H, Fixed, 95% CI	%
1	Biton et al. [11]	2011	22	176	13	180	1.73 [0.90, 3.33]	27.3
2	Brodie et al. [10]	2009	32	156	19	157	1.70 [1.01, 2.86]	40.3
3	Elger et al. [14]	2010	25	262	5	133	2.54 [0.99, 6.48]	14.1
4	Glauser et al. [5]	2008	18	74	8	64	1.95 [0.91, 4.17]	18.3
Total events			97	668	45	534	1.87 [1.33, 2.62]	100

Heterogeneity: χ = 0.61, d.f. = 3 (P = 0.89); I² = 0%. Test for overall effect: Z = 3.64 (P = 0.0003).